Home Webinars CEORoadshow 2021 Webinar Series Presents Cardiol Therapeutics, Inc. (NASDAQ: CRDL) (TSX: CRDL)

CEORoadshow 2021 Webinar Series Presents Cardiol Therapeutics, Inc. (NASDAQ: CRDL) (TSX: CRDL)

66
0

This webinar will highlight Cardiol’s current pipeline and the latest developments at the company.

To register for or join any of the upcoming webinars, please click on the individual link below for the dates you would like to attend and register.

September 2021 Webinar Dates

This Webinar is part of the CEO Roadshow Webinar Series where we feature small and mid-cap stocks that are on the verge of a breakout or have other near-term developments making them an attractive long-term investment opportunity.

In this webinar, we will be joined by Mr. David Elsley, CEO of Cardiol Therapeutics.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (“CVD”). The Company’s lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a Phase II/III outcomes study (the LANCER trial). The LANCER trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.

Cardiol has also received clearance from the FDA for its investigational new drug (“IND”) application for a Phase II international trial that will investigate the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure – a leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

LEAVE A REPLY

Please enter your comment!
Please enter your name here